STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematologic Malignancies and Patients With Solid Tumors

NCT00088101 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Hematological Malignancies
Leukemia
Lymphoma
Metastatic or Unresectable Solid Tumors

Interventions

DRUG: STA-5312

Sponsor

Synta Pharmaceuticals Corp.